Anbio Biotechnology
NNNN
$6.61
$0.040.61%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 136.53% | 136.53% | 91,725.00% | 91,725.00% | -84.81% |
| Total Depreciation and Amortization | -- | -- | -48.39% | -48.39% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -742.68% | -742.68% | -278.87% | -278.87% | -- |
| Change in Net Operating Assets | -562.24% | -562.24% | -153.68% | -153.68% | 106.93% |
| Cash from Operations | -71.90% | -71.90% | -136.68% | -136.68% | 96.10% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -91.27% | -91.27% | -59.44% | -59.44% | 183.75% |
| Cash from Investing | -91.27% | -91.27% | -59.44% | -59.44% | 183.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 55.04% | 55.04% | -- | -- | -- |
| Cash from Financing | 55.12% | 55.12% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -82.01% | -82.01% | -123.45% | -123.45% | 530.65% |